Wide Ranks

LVTX

LAVA Therapeutics N.V.

1.60

Top Statistics
Market Cap 42 M Forward PE -0.9390 Revenue Growth 0.00 %
Current Ratio 6.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.43 Enterprise / Revenue -5.21 Price To Sales Trailing12 Months 5.69
Profitability
Profit Margins 0.00 % Operating Margins -371.48 %
Balance Sheet
Total Cash 86 M Total Cash Per Share 3.30 Total Debt 6 M
Total Debt To Equity 14.37 Current Ratio 6.39 Book Value Per Share 1.63
All Measures
Short Ratio 41.00 % Message Board Id finmb_546792242 Shares Short Prior Month 2426
Return On Equity -0.4530 City Utrecht Uuid f272303e-4305-36b0-b7df-26c82acd7c44
Previous Close 1.55 First Trade Date Epoch Utc 1 B Book Value 1.63
Beta 0.4800 Total Debt 6 M Volume 26774
Price To Book 0.9810 Fifty Two Week Low 1.35 Total Cash Per Share 3.30
Total Revenue 7 M Shares Short Previous Month Date 1 B Target Median Price 5.50
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -371.48 %
Target Mean Price 6.64 Net Income To Common -24183000 Short Percent Of Float 0.0016
Implied Shares Outstanding 26 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 38430 Average Volume10days 38430 Total Cash 86 M
Next Fiscal Year End 1 B Revenue Per Share 0.2740 Held Percent Insiders 0.2872
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.55 Target Low Price 5.40 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.71 Open 1.60 Free Cashflow -17983250
Dividend Yield 0.00 % Return On Assets -0.1599 Time Zone Short Name EST
Trailing Eps -0.8900 Day Low 1.58 Address1 Yalelaan 62
Shares Outstanding 26 M Price Hint 4 Target High Price 10.15
Website https://www.lavatherapeutics.com 52 Week Change 0.0554 Average Volume 48106
Forward Eps -1.94 Recommendation Key none Quick Ratio 623.30 %
Is_sp_500 False Regular Market Day High 1.71 Profit Margins 0.00 %
Debt To Equity 14.37 Fifty Two Week High 6.47 Day High 1.71
Shares Short 26439 Regular Market Open 1.60 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -5.21 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0010 Operating Cashflow -27081000 Currency USD
Time Zone Full Name America/New_York Market Cap 42 M Is_nasdaq_100 False
Zip 3584 CM Quote Type EQUITY Industry Biotechnology
Long Name LAVA Therapeutics N.V. Regular Market Day Low 1.58 Held Percent Institutions 0.3188
Current Price 1.60 Enterprise To Ebitda 1.43 Financial Currency USD
Current Ratio 6.39 Gross Margins 97.78 % Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country Netherlands Float Shares 12 M
Two Hundred Day Average 2.19 Enterprise Value -38561284 Price To Sales Trailing12 Months 5.69
Forward PE -0.9390 Regular Market Volume 26774 Ebitda -26883000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
LAVA Therapeutics N.

V.

, a clinical-stage immuno-oncology company, focuses on developing cancer treatments.

The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies.

LAVA Therapeutics N.

V.

has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co.

, Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207.

LAVA Therapeutics N.

V.

was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.